Catheter Precision, Inc. Press Release

FORT MILL, S.C., May 01, 2025 -- Catheter Precision, Inc. (VTAK - NYSE/American), a US-based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, announced that new clinical data about VIVO is available.

Catheter Precision previously announced that data was compiled and presented during three different abstract sessions on its VIVO product. VIVO is a non-invasive mapping system used to identify areas of ventricular arrhythmia prior to a procedure. Previously released data documents that VIVO is over 95% accurate and reduces procedure time by almost 30%. This new data comes from leading industry physicians including: Professor Sabine Ernst (UK), Professor Tarv Dhanjal (UK) and Dr. Dhanunjaya Lakkireddy (USA).

This new data highlights additional benefits of VIVO that include:

• When VIVO is used pre-procedurally, there are statistically significant differences in procedural outcomes.
• VIVO provides the ability to identify arrhythmia sources that could not otherwise be identified because the patient does not have frequent arrhythmias, or the patient has difficult anatomy.
• There was high accuracy in a new patient population (ischemic ventricular tachycardia) that also shows successful long-term outcomes.
   

The data from these abstracts is currently being written into a format that can be submitted to industry journals for more detailed publications.

CEO of Catheter Precision, David Jenkins, said, “New clinical data is the cornerstone of what we do. This new data demonstrates to physicians that not only does VIVO work as intended, but that using VIVO may improve outcomes for patients. Just as importantly, we continue to see evidence of meaningful reduction in procedure time, and in the VT cases we are seeing significantly less burden of VT during the procedure. We will continue to generate new data for publications and look forward to exploring next studies that confirm the data that was presented in these abstracts.”

About VIVO™
Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark.

About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.